secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0001493152-24-047994
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum
--------------------------------------------------------------------------------

- Nasdaq letter on Nov 21, 2024: stockholders' equity fell below $2.5M required for continued listing.
- Company does not meet market value of listed securities or net income alternatives.
- Must submit compliance plan by Jan 6, 2025; Nasdaq may grant up to 180-day extension.
- If plan not accepted, Company may appeal to Nasdaq Hearings Panel.
- Stock continues trading under GTBP; no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315224047994/0001493152-24-047994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315224047994/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-047994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer